Paragon 28 (FNA) Circular External Fixation System FDA Cleared

November 16, 2021by Jim Edson
P28 Training

Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced today that the U.S. Food and Drug Administration (FDA) has given 501(k) marketing clearance to its Circular External Fixation System. The Circular External Fixation System, expected to commercially launch in early 2022, will complement Paragon 28’s comprehensive internal fixation portfolio and further expands Paragon 28’s product offering in the foot and ankle space.

Brendan Shook, Paragon 28’s Executive Vice President of Marketing commented, “We are excited to receive FDA clearance for P28’s first external fixation product offering. We believe it will be a nice complement to our existing product portfolio, and will further P28’s mission to improve foot and ankle patient outcomes. We look forward to the product line launching in the first half of 2022.”

Learn More Click Here

Paragon 28 Logo
14445 Grasslands Dr. Englewood, CO 80112

Follow us:


The name “Paragon 28” was chosen by design — to never lose focus on our goal to advance the science of foot and ankle surgery.

© 2024 Paragon 28, Inc.

Privacy Policy